Moderna Recursion: Which Cutting-Edge Path Is Best in 2026
Two biotech powerhouses take very different routes: Moderna builds medicines with mRNA, while Recursion uses machine ...
The yield curve tracks expectations for growth and inflation, guiding risk appetite and index moves. This note explains typical yield-curve signals.
28,655 articlesTwo biotech powerhouses take very different routes: Moderna builds medicines with mRNA, while Recursion uses machine ...
Moldova’s parliament elects 44-year-old businessman Vasile Tofan as prime minister after a 53-21 vote. Investors and ...
Arweave's AR token is in focus as investors map a path for 2025 through 2030. This piece outlines the key drivers, sc...
A fresh national analysis finds childcare costs far outpace income growth, forcing many families to rethink childrear...
Qualcomm is refocusing from smartphones to robotics and AI-ready chips, while its shares trade at a low multiple amid...
Venture firm Andreessen Horowitz and a growing mix of banks push a five-year horizon for autonomous AI agents to func...
Dell Technologies rides a booming AI infrastructure cycle into 2027, with a record AI backlog and ambitious revenue t...
Bank of America initiates coverage on Salesforce with an Underperform rating and a $160 price target, highlighting un...
Microsoft is recalibrating its internal AI tools as costs climb, signaling a broader shift in how AI is priced into b...
Palantir maintains AI-driven momentum into 2026, but investors weigh continued growth against contracts and policy ri...
Bagel prices are climbing in 2026, but the bagel remains a daily staple and a symbol of immigrant business resilience...
When billionaires pile into certain stocks, it grabs attention. This article breaks down why this happens, what it me...